Conclusions
knee osteoarthritis
ADVERSE EVENTS, KNEE OSTEOARTHRITIS
In contrast to the original published article by Sánchez and colleagues, our analysis of Study PRGF (originally coded as BTI-01-EC/07/ART) found no statistically significant differences between plasma rich in growth factors and hyaluronic acid in adults with knee osteoarthritis on any of the prespecified outcomes, included the primary efficacy variable. Serious or unexpected adverse events were rare and equally distributed between both interventions. Notwithstanding, further research should focus on finding out the real rate of persistent harms and the particular profile of adverse events linked to each treatment. Health professionals, especially in this case orthopaedic surgeons, but also researchers and decision-makers should be aware of the potential weaknesses in a priori high-quality research. It is highly convenient that all systematic reviews including the present clinical trial update their results in the light of this new evidence. In the same way, any other clinical trial or review based to some extent on the findings of this study is also called to re-assess its conclusions. Also, sharing the imperative demand by many other research teams, health authorities are strongly encouraged to make compulsory free access to protocols and raw data supporting subsequent publications.As Le Noury and colleagues rightly stated in their pioneering report [